drugset / Trial / NCT05647811
Study of NM8074 in Adult C3 Glomerulopathy Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.
Timeline
- Start
- 2027-05
- Primary completion
- 2029-08
- Completion
- 2030-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RUXOPRUBART | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | RUXOPRUBART | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | RUXOPRUBART | Monoclonal antibody | 20 mg/kg | Intravenous |